Clinical trial NCT02204072: BI836845 Plus Enzalutamide in Castrate Resistant Prostate Cancer (CRPC)
Official title: A Phase Ib/II, Multicentre, Open Label, Randomized Study of BI 836845 in Combination With Enzalutamide, Versus Enzalutamide Alone, in Metastatic Castration-Resistant Prostate Cancer (CRPC) Following Disease Progression on Docetaxel-Based Chemotherapy and Abiraterone
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Prostatic Neoplasms, Castration-Resistant
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
First posted: 2014-07-30
Enrollment: 120
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The overall aim of the trial is to investigate the safety and anti-tumour activity of an experimental drug BI 836845 taken together with the prostate cancer drug, enzalutamide, compared to enzalutamide given alone, in castrate resistant prostate cancer (CRPC) patients that have previously been treated and failed on docetaxel and abiraterone treatments. Initially, a tolerability and safety phase (phase Ib escalation) will be performed to confirm the maximum tolerated dose (MTD), or recommended doses of both BI 836845 and enzalutamide that can be taken together.

Once the MTD, or recommended phase II dose, have been determined an expansion cohort will also be explored (phase Ib expansion) in CRPC patients already taking enzalutamide and have a rise in prostate serum antigen (PSA) levels. Patients may not have received prior docetaxel or abiraterone. Patients in this cohort will receive the MTD, or recommended phase II dose, of BI 836845 and enzalutamide determined in the phase Ib escalation phase.

The randomised trial (phase II) will be an open label, parallel group study design in a 1:1 ratio to which patients will receive either BI 836845 plus enzalutamide (Arm A) at the MTD/recommended doses, or enzalutamide alone (Arm B).

In all parts of the trial safety, anti-tumour activity will be assessed, in addition to circulating tumour cells (CTC), prostate serum antigen (PSA) response and progression, and determination of Overall Survival (OS).


Eligibility criteria: Inclusion criteria:

* The patient has histologically, or cytologically, confirmed adenocarcinoma of the prostate.
* Male patient aged, equal to, or more than,18 years old.
* Patients with radiographic evidence of metastatic prostate cancer (stage M1 or D2). Distant metastases evaluable by radionuclide bone scan, CT scan, or MRI within 28 days before the start of study treatment.
* Patients with a prostate serum antigen (PSA), equal to, or more than, 5 nanograms per mililiter (ng/mL).
* Patients with prior surgical or chemical castration with a serum testosterone of \<50 ng/mL. If the method of castration is luteinizing hormone releasing level hormone (LHRH) agonists, the patient must be willing to continue the use of LHRH agonists during protocol treatment.
* Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1.
* Cardiac left ventricular function with resting ejection fraction \>50% as determined by echocardiogram (ECHO) or multigated acquisition scan (MUGA).
* Absolute neutrophil count (ANC) \>=1500/microlitre (uL).
* Haemoglobin \>=9 gram per deciliter (g/dL).
* Platelets \>=100,000/uL.
* Bilirubin \<= 1.5 times the upper limit of normal (ULN).
* Aspartate transaminase (AST) and alanine transaminase (ALT) \<= 2.5 times the ULN(or \<= 5 times the ULN if liver metastases are present).
* Creatinine \<= 1.5 x ULN.
* International normalized ratio (INR) \</= 2 and a partial thromboplastin time (PTT) \</= 5 seconds above the ULN (unless on oral anticoagulant therapy). Patients receiving full dose anticoagulation therapy are eligible provided they meet all other criteria, are on a stable dose of oral anticoagulant or low molecular weight heparin (except warfarin or coumarin-like anticoagulants, which are not permitted).
* Fasting plasma glucose \< 8.9 millimols per liter (mmol/L) (\< 160 milligrams per deciliter (mg/dL) and glycated haemoglobin (hemoglobin A1c (HbA1c)) \< 8.0%.

Inclusion criteria only for patients entering phase Ib escalation and phase II:

* Patients who have disease progression during, or after, receiving docetaxel and have had at least 12 weeks of treatment and in the opinion of the investigator are unlikely to derive significant benefit from additional docetaxel-based therapy, or were intolerant to therapy with this agent.
* Patients who have disease progression during, or after, receiving abiraterone treatment in any setting.
* Patients must have progressive disease defined as at least one of the following:

  1. Progressive measurable disease: using conventional solid tumour criteria RECIST 1.1.
  2. Bone scan progression: at least two new lesions on bone scan, plus a rising PSA as described in (c) below.
  3. Increasing PSA level: at least two consecutive rising PSA values over a reference value (PSA #1) taken at least 1 week apart. A third PSA (PSA #3) is required to be greater than PSA #2; if not, a fourth PSA (PSA #4) is required to be greater than PSA #2.

Inclusion criterion only for patients entering phase Ib expansion cohort:

* Patients must be receiving continuous enzalutamide treatment and show a rise in PSA level: at least two consecutive rising PSA values over a reference value (PSA #1) taken at least 1 week apart. A third PSA (PSA #3) is required to be greater than PSA #2; if not, a fourth PSA (PSA #4) is required to be greater than PSA #2.
* Archive tumour tissue is available prior to recruitment for pharmacogenomic tests

Exclusion criteria:

* Prior therapy with agents targeting Insulin Growth Factor (IGF) and/or Insulin Growth Factor Receptor (IGFR) pathway.
* Patients that have been treated with any of the following within 4 weeks of starting trial treatment: chemotherapy, immunotherapy, biological therapies, molecular targeted, hormone therapy (except LHRH agonists and LHRH antagonists), radiotherapy (except in case of localized radiotherapy for analgesic purpose or for lytic lesions at risk of fracture which can then be completed within 2 weeks prior to study treatment).
* Use of any investigational drug within 4 weeks before start of trial treatment or concomitantly with this trial.
* Patients that have been treated with strong cytochrome P450, family 2, subfamily C, polypeptide 8 (CYP2C8) inhibitors, CYP2C8 inducers, within 2 weeks of starting the trial treatment.
* Fridericia´s Corrected QT interval (QTcF) prolongation \> 450 ms or QT prolongation deemed clinically relevant by the investigator (e.g., congenital long QT syndrome). The QTcF will be calculated as the mean of the 3 ECGs taken at screening.
* Patients with small cell or neuroendocrine tumours.
* Patients with known or suspected leptomeningeal metastases.
* Uncontrolled or poorly controlled hypertension.
* Known human immunodeficiency virus infection or acquired immunodeficiency syndrome-related illness.
* Patients with epilepsy, seizures, or predisposing factors for seizure as judged by the investigator.
* Patients unable to comply with the protocol as judged by the investigator.
* Active alcohol or active drug abuse as judged by the investigator.
* A history of allergy to human monoclonal antibodies.
* Patients who are sexually active and unwilling to use a medically acceptable method of contraception, e.g. condom plus spermicide use for participating males, plus another form of birth control such as implants, injectables, combined oral contraceptives, intrauterine devices for female partners, during the trial and for at least three months after end of active therapy. Men unwilling to agree to not donate sperm while on trial drug and up to 6 months following the last dose of trial drug.
* Previous or concomitant malignancies at any other site with the exception of the following:

  * benign basal cell carcinoma
  * benign low grade transitional cell carcinoma of the bladder
  * other effectively treated malignancy that has been in remission for more than 5 years and is considered to be cured
* Only for patients entering phase Ib dose escalation and phase II cohorts:
* Patients who have received more than 2 prior non-docetaxel containing cytotoxic chemotherapy regimens for Metastatic Castration-Resistant Prostate Cancer (mCRPC).
* Patients who have received a taxane based treatment or abiraterone, within 4 weeks before start of study treatment.
* Patients that have received prior enzalutamide in any setting will not be eligible.

Exclusion criterion only for patients entering phase Ib expansion cohort:

- Patients that have received prior taxane-based chemotherapy or abiraterone in any setting will not be eligible for the expansion cohort.

Additional exclusion criterion for patients undergoing tumour biopsy:

* For patients that are to undergo the tumour biopsy, a history of a hereditary bleeding disorder, or clinically relevant major bleeding event in the past 6 months, as judged by the investigator.
* Further exclusion criteria apply

Primary outcomes:
measure: Number of patients with dose limiting toxicities (phase Ib escalation)
timeFrame: 6 months
measure: Maximum tolerated dose (phase Ib escalation)
timeFrame: 6 months
measure: Prostate Surface Antigen (PSA) response - defined as a decline in PSA value >50% (which is confirmed by a second value 3 to 4 weeks apart) (phase Ib expansion)
timeFrame: Up to 3 years
measure: Radiological Progression free survival - time from randomisation to disease progression based on investigator assessment in bone, or soft tissue, or death (phase II)
timeFrame: Up to 3 years
Secondary outcomes:
measure: Overall survival - defined as the time from randomisation to death from any cause (phase II)
timeFrame: Up to 3 years
measure: Time to prostate serum antigen (PSA) progression - defined as the date that a 25% or greater increase in PSA, and an absolute increase of 2 ng/mL or more from the nadir, is documented, which is confirmed by a second value 3 or more weeks later (phase II)
timeFrame: Up to 3 years
measure: Maximum decline in PSA - compared to baseline that occurs at any point after treatment start (phase II)
timeFrame: Up to 3 years
measure: Percentage change in PSA - from baseline to week 12 of treatment (phase II)
timeFrame: Up to 3 years
measure: CTC response-CTC reduction compared to baseline for at least one time point after treatment start assessed by maximum change in CTC counts compared to baseline that occurs at any point after treatment start (phase II)
timeFrame: Up to 3 years
measure: Radiological progression free survival - defined as time from start of treatment to disease progression based on investigator assessment in bone based on PCWG2 or soft tissue based on modified RECIST 1.1 where applicable, or death (phase Ib expansion)
timeFrame: Up to 3 years
measure: Changes in CTC response - CTC reduction compared to baseline for at least one time point after treatment start assessed by CTC decline from, equal to, or more than, 5 to <5 cells per 7.5ml blood (phase II)
timeFrame: Up to 3 years
measure: Changes in circulating tumour cells (CTC) response - CTC reduction compared to baseline for at least one time point after treatment defined as CTC decline from, equal to, or more than, 5 to <5 cells per 7.5ml blood (phase Ib expansion)
timeFrame: Up to 3 years
measure: PSA response - defined as a decline in PSA value >50%, which is confirmed by a second value 3 to 4 weeks apart (phase II)
timeFrame: Up to 3 years
measure: Radiological progression free survival - defined as time from randomisation to disease progression based on central review in bone based on PCWG2 or soft tissue based on modified RECIST 1.1 where applicable, or death (phase II)
timeFrame: Up to 3 years
Other outcomes:
Locations:
city: Detroit
country: United States
facility: Karmanos Cancer Institute
state: Michigan
city: New York
country: United States
facility: NewYork-Presbyterian/Weill Cornell Medical Center
state: New York
city: Portland
country: United States
facility: Oregon Health and Sciences University
state: Oregon
city: Hong Kong
country: Hong Kong
facility: Prince of Wales Hospital
city: Hong Kong
country: Hong Kong
facility: Queen Mary Hospital
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
city: Seoul
country: Korea, Republic of
facility: Asan Medical Center
city: Rotterdam
country: Netherlands
facility: Erasmus MC - Daniel den Hoed
city: Tilburg
country: Netherlands
facility: Tweesteden Ziekenhuis, locatie Tilburg
city: Singapore
country: Singapore
facility: National Cancer Centre Singapore
city: Singapore
country: Singapore
facility: OncoCare Cancer Centre
city: Singapore
country: Singapore
facility: Tan Tock Seng Hospital
city: Barcelona
country: Spain
facility: Hospital Vall d'Hebron
city: Barcelona
country: Spain
facility: Hospital Clínic de Barcelona
city: Barcelona
country: Spain
facility: Hospital Santa Creu i Sant Pau
city: L'Hospitalet de Llobregat
country: Spain
facility: Hospital Duran i Reynals
city: Madrid
country: Spain
facility: Hospital General Universitario Gregorio Marañón
city: Madrid
country: Spain
facility: Hospital Ramón y Cajal
city: Valencia
country: Spain
facility: Instituto Valenciano de Oncología
city: Taichung
country: Taiwan
facility: Taichung Veterans General Hospital
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
city: Taipei
country: Taiwan
facility: Taipei Veterans General Hospital
city: Bebington, Wirral
country: United Kingdom
facility: The Clatterbridge Cancer Centre
city: Cardiff
country: United Kingdom
facility: Velindre Cancer Centre
city: Manchester
country: United Kingdom
facility: The Christie Hospital
city: Oxford
country: United Kingdom
facility: Churchill Hospital
city: Sutton
country: United Kingdom
facility: The Royal Marsden Hospital, Sutton
Study officials:
affiliation: Boehringer Ingelheim
name: Boehringer Ingelheim
role: STUDY_CHAIR
References: